cytochrome P450 family 46 subfamily A member 4, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP46A4P profile across patient tissues and cancer cell-line models. CYP46A4P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CYP46A4P is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, CYP46A4P RNA expression shows 6,741 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight MESO, HNSC, and KIRP as cancer lineages where CYP46A4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP46A4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP46A4P survival associations across molecular data types. CYP46A4P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP46A4P RNA expression–survival associations across cancer types. High CYP46A4P expression shows unfavorable associations in MESO, STAD, KIRP, CESC and SARC, but favorable associations in ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CYP46A4P RNA expression.
This table summarizes CYP46A4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP46A4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP46A4P shows lower tumor expression in BRCA and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher CYP46A4P RNA expression in tumor versus normal tissue (log2 FC = +0.069, t-test p = .027).
This table shows molecular features associated with CYP46A4P in patient tissues and cancer cell lines. In patient samples, CYP46A4P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
